A recent research has found that whether SARS-CoV-2 infection becomes severe or not depends not only on the strong immune activation but also on the dysfunctional endothelium, in other words, the vascular system.
Feb 25, 2021
Earlier diagnosis may be key to effective treatment
A tau-directed monoclonal antibody did not slow the advancement of progressive supranuclear palsy (PSP), a phase II study found.
“Tilavonemab a monoclonal antibody that binds an epitope containing amino acids 25–30 at the N-terminus of tau in doses high enough to bind 50% or more of tau in the cerebrospinal fluid did not affect progression of the disorder,” wrote Gunter Hoglinger, MD, of Hannover Medical School in Germany, and co-authors in
Hoglinger and colleagues conducted a randomized, placebo-controlled, double-blind study at 66 international sites. The trial was terminated after pre-specified futility criteria were met by the second interim analysis.